The New York-based law firm is currently evaluating whether the terms of these pending deals adequately protect the interests of ordinary shareholders. Specifically, the investigations center on concerns that insiders may be positioned to receive disproportionate financial benefits, while restrictive deal terms could effectively stifle superior competing offers for the companies. Arcosa is slated for sale to CRH at $150.00 per share, Caesars Entertainment to Fertitta Entertainment at $31.00 per share, and Apogee Therapeutics to AbbVie at $135.11 per share.
Halper Sadeh Launches Investigations into Arcosa, Caesars, and Apogee
Conflict serves as the catalyst for three new investigations launched by Halper Sadeh LLC, as the investor rights firm scrutinizes the proposed acquisitions of Arcosa, Caesars Entertainment, and Apogee Therapeutics for potential breaches of fiduciary duty and violations of federal securities law.
On behalf of affected investors, Halper Sadeh LLC is exploring legal avenues to seek increased consideration or additional disclosures regarding these transactions. The firm, which operates on a contingent fee basis, invites shareholders to review their options regarding potential litigation or corporate reform efforts. Attorneys Daniel Sadeh and Zachary Halper are leading the inquiries from the firm's One World Trade Center office, signaling a push for greater transparency in the execution of these high-profile corporate sales.
Comments (0)
No comments yet. Be the first!